The World Health Organization issued its first comprehensive guidelines on obesity management, stating that long-term treatment with GLP-1 receptor agonists is an appropriate option as obesity is reframed as a chronic disease. The guidance endorses use of GLP-1s within broader, sustained care plans while noting limited long-term safety data. The document signals a major policy shift that may influence national treatment frameworks and payer deliberations. WHO and JAMA commentary emphasized the need for integrated care, and the agency urged research into long-term outcomes and equitable access.